| Macular retinal edema
Lucentis vs Ozurdex
Side-by-side clinical, coverage, and cost comparison for macular retinal edema.Deep comparison between: Lucentis vs Ozurdex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOzurdex has a higher rate of injection site reactions vs Lucentis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ozurdex but not Lucentis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lucentis
Ozurdex
At A Glance
Intravitreal injection
Monthly
VEGF-A antagonist
Intravitreal injection
Corticosteroid
Indications
- Exudative age-related macular degeneration
- Macular retinal edema
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
- Macular retinal edema
- Uveitis
Dosing
Exudative age-related macular degeneration 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly; less frequent dosing with regular assessment may be considered after 3-4 initial monthly doses.
Macular retinal edema 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly.
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL of 6 mg/mL) intravitreal injection once monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly for up to 3 months; retreat as needed.
Macular retinal edema, Uveitis One 0.7 mg intravitreal implant injected into the vitreous cavity under controlled aseptic conditions; each applicator is single-use and treats one eye only.
Contraindications
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab or any excipient in LUCENTIS
- Active or suspected ocular or periocular infections, including viral diseases of the cornea and conjunctiva (active epithelial herpes simplex keratitis, vaccinia, varicella), mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratios greater than 0.8
- Torn or ruptured posterior lens capsule due to risk of migration into the anterior chamber
- Known hypersensitivity to any components of this product
Adverse Reactions
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, intraocular inflammation, cataract, foreign body sensation in eyes, eye irritation, lacrimation increased, nasopharyngitis, headache
Serious Endophthalmitis, retinal detachment, rhegmatogenous retinal detachment, iatrogenic traumatic cataract, thromboembolic events, fatal events in patients with DME and DR
Postmarketing Tear of retinal pigment epithelium in patients with neovascular AMD
Most common (>=20%) Cataract, increased intraocular pressure, conjunctival hemorrhage
Serious Elevated IOP with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection (including herpes simplex), globe perforation
Postmarketing Endophthalmitis, retinal detachment, implant misplacement with ocular tissue injury, device dislocation with corneal edema or decompensation, hypotony of the eye
Pharmacology
Ranibizumab is a VEGF-A antagonist; a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lucentis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (0/12)
Ozurdex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lucentis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ozurdex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lucentis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Ozurdex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Ozurdex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LucentisView full Lucentis profile
OzurdexView full Ozurdex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.